Aristotle University Of Thessaloniki (AUTH)
Συμβολή στη μελέτη του θεραπευτικού αποτελέσματος και της ασφάλειας της αμφοτερικίνης Β στη συμπτωματική λεϊσμανίωση του σκύλου (Leishmania infantum) και η επίδρασή της, με ή χωρίς εναλαπρίλη, στη λειτουργία των νεφρών
Abstract
dc:descriptionCanine leishmaniasis (CL), as it appears in the Mediterranean basin, is caused by the intracellular protozoan parasite Leishmania infantum. Today, it is by all means the most common arthropod - borne infectious disease in Greece. Its transmission among various mammalian species is carried out by the bites of blood-sucking sandflies (Phlebotomus sp.), harboring the flagellated promastigotes. The pathogenesis of overt disease should be focused on the overproduction of IgG antibodies against parasitic antigens, assumingly exemplifying a Th2 immune response from the part of the host that may result in the deposition of circulating or in-situ forming immunocomplexes, usually targeting the skin, eyes, joints and kidneys. In the latter, chronic glomerulonephritis (e.g. mesangioproliferative, membranoproliferative, membranous, minimal change glomerulopathy) and eventually glomerulosclerosis and tubulointerstitial fibrosis may lead to chronic renal failure, end-stage renal disease and the death of the animal. The resultant proteinuria, one of the most common findings in the laboratory evaluation of CL cases, is partly responsible for the deterioration of glomerular lesions. Meglumine antimoniate, allopourinol, aminosidine and amphotericin B (AmB) are today’s cornerstone in the treatment of CL, though not associated with encouraging results regarding the parasitological cure rate and the definitive switching of Th2 to Th1 immunological response. Consequently, life-long therapy with allopurinol is usually mandatory to avoid clinical relapses. Therapeutic experience with human visceral leishmaniasis and the emergence of resistant L. infantum strains to antimonials have encouraged the use of the antifungal agent AmB in the treatment of CL. The commercially available lipid form (Ambisome®) or the emulsion of its desoxycholate salt with lipids for parenteral nutrition (Fungizone® plus Intralipid®) have been formulated in an attempt to lower the risk of nephrotoxicosis, mainly imposed via glomerular vasoconstriction with a subsequent reduction of glomerular filtration rate (GFR). The goals of this prospective, open label and single-blinded but not placebo-controlled study were the following: 1) the evaluation of the clinical and parasitological efficacy and safety of lipid-formulated AmB in a large number of dogs with symptomatic CL (L. infantum), by applying a standard dosage scheme, 2) its effect on GFR and the level of glomerulonephritis-associated proteinuria, with or without enalapril, and 3) the long-term evaluation of enalapril therapy, with or without allopurinol, on both proteinuria level and GFR. Enalapril is an angiotensin converting enzyme inhibitor (ACEI) with renoprotective properties that has been known to effectively attenuate proteinuria in humans, dogs and laboratory rodents with natural or experimental glomerulonephritis, mainly via its vasodilatory effect on the efferent glomerular arterioles, which opposes that of AmB.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2006
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Κουτίνας, Χρήστος
- Koutinas, Christos
Subjects
dc:subject × 20- Λεϊσμανίωση
- Σκύλοι
- Αμφοτερικίνη Β
- Πρωτεϊνουρία
- Σπειραματονεφρίτιδα
- Εναλαπρίλη
- Παρασιτολογική ίαση
- Λόγος πρωτεϊνών/κρεατινίνης
- Leishmaniasis
- Dogs
- Amphotericin B
- Proteinuria
- Glomerulonephritis
- Enalapril
- Parasitological cure
- Protein/creatinine ratio
- Γεωπονικές Επιστήμες και Κτηνιατρική
- Κτηνιατρική
- Agricultural and Veterinary Sciences
- Veterinary Science
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/15261